Mattias Törnerud, Capio St Görans sjukhus AB, Stockholm. Invasiv tryckmätning FFR



Similar documents
Non-invasive FFR Using Coronary CT Angiography and Computational Fluid Dynamics Predicts the Hemodynamic Significance of Coronary Lesions

Cilostazol versus Clopidogrel after Coronary Stenting

FFR CT : Clinical studies

PRECOMBAT Trial. Seung-Whan Lee, MD, PhD On behalf of the PRECOMBAT Investigators

Non-invasive functional testing in 2014

For the NXT Investigators

Scott Hubbell, MHSc, RRT-NPS, C-NPT, CCT Clinical Education Coordinator/Flight RRT EagleMed

MYOCARDIAL PERFUSION COMPUTED TOMOGRAPHY PhD course in Medical Imaging. Anne Günther Department of Radiology OUS Rikshospitalet

Is Stenting or Coronary Artery By-pass Grafting the Better Treatment for This Patient?

Copenhagen University Hospital Rigshospitalet Aarhus University Hospital Skejby Denmark

Ostial LAD: Single stent approach is the best. Antonio A. Pocoví, MD, FSCAI, MTSAC, Advisory Council Member, CACI

Dual Antiplatelet Therapy. Stephen Monroe, MD FACC Chattanooga Heart Institute

MEDICAL POLICY No R1 DRUG-ELUTING STENTS FOR ISCHEMIC HEART DISEASE

Diagnostic and Therapeutic Procedures

Cardiac Assessment for Renal Transplantation: Pre-Operative Clearance is Only the Tip of the Iceberg

Main Effect of Screening for Coronary Artery Disease Using CT

PCI vs. CABG for Left Main Disease

RIBS V. Fernando Alfonso MD, PhD, FESC Hospital Universitario La Princesa Madrid.

2/20/2015. Cardiac Evaluation of Potential Solid Organ Transplant Recipients. Issues Specific to Transplantation. Kidney Transplantation.

CORONARY ARTERY BYPASS GRAFTS, STENTS, AND EXTRACORONARY CARDIAC DZ. Charles White MD

Efficient Evaluation of Chest Pain

Section 8: Clinical Exercise Testing. a maximal GXT?

4/7/2015. Cardiac Rehabilitation: From the other side of the glass door. Chicago, circa Objectives. No disclosures, no conflicts

Drug-Eluting Balloons. Klaus Bonaventura Department of Cardiology and Angiology Heart Thorax Vascular Center, Klinikum Ernst von Bergmann, Potsdam

Coronary Bifurcation Treatment: Update from the European Bifurcation Club. Remo Albiero, MD Ist. Clinico S. Rocco Brescia (Italy)

OCT STEMI: OCT guidance during stent implantation

123 Main St NY, New York ph: (202) fax: (202)

06 Validation of risk prediction model

Duration of Dual Antiplatelet Therapy After Coronary Stenting

12 Lead ECGs: Ischemia, Injury & Infarction Part 2

Is it really so? : Varying Presentations for ACS among Elderly, Women and Diabetics. Yen Tibayan, M.D. Division of Cardiovascular Medicine

6/5/2014. Objectives. Acute Coronary Syndromes. Epidemiology. Epidemiology. Epidemiology and Health Care Impact Pathophysiology

The Pantera Lux Paclitaxel DEB Device Description and Clinical Studies. Christoph Hehrlein, University Clinic Freiburg i.br.

Do método diagnóstico ao terapêutico: a História da Hemodinâmica e da Cardiologia Intervencionista, em 15 minutos. Eulógio E Martinez

Clinical Research Intracoronary Stenting with Crushing in Coronary Artery Bifurcation Lesions: Initial Results and Medium-Term Follow Up

Objectives. Preoperative Cardiac Risk Stratification for Noncardiac Surgery. History

Using Clinical Registries to Create Evidence-based Health Care Policy : Experiences from Ontario, Canada

A Post-market Study to Assess the STENTYS Self-exPanding COronary Stent In AcuTe myocardial InfarctiON in Real Life APPOSITION III

Noninvasive testing can provide useful information for

ST Segment Elevation Nothing is ever as hard (or easy) as it looks

2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention

LEADERS: 5-Year Follow-up

Renovascular Hypertension

The left internal mammary artery (LIMA) is the

Cardiac Rehabilitation The Best Medicine for Your CAD Patients. James A. Stone

Repeat Coronary Revascularization Procedures after Successful Bare-Metal or Drug-Eluting Stent Implantation

Majestic Trial 12 Month Results

Intracoronary Stenting and. Robert A. Byrne, Julinda Mehilli, Salvatore Cassese, Franz-Josef Neumann, Susanne Pinieck, Tomohisa Tada,

on behalf of the AUGMENT-HF Investigators

Health Related Quality of Life and U.S. Economic Outcomes of PCI with Drug-Eluting Stents vs. Bypass Surgery: 1-Year Results from the SYNTAX Trial

Abstract. n engl j med 360;3 nejm.org january 15,

Early And Late Outcome For Single Versus Double Stenting For Bifurcational Coronary Artery Lesions

Cardiac CT Emerging Role and Current Indications

Atrial Fibrillation 2014 How to Treat How to Anticoagulate. Allan Anderson, MD, FACC, FAHA Division of Cardiology

CARDIAC RISKS OF NON CARDIAC SURGERY

How should we treat atrial fibrillation in heart failure

Pre-Operative Cardiac Evaluation Kalpana Jain, MD

The heart walls and coronary circulation

Antonio Colombo MD on behalf of the SECURITY Investigators

CHAPTER 9 DISEASES OF THE CIRCULATORY SYSTEM (I00-I99)

INTRODUCTION TO EECP THERAPY

BASIC STANDARDS FOR RESIDENCY TRAINING IN CARDIOLOGY

Osama Jarkas. in Chest Pain Patients. STUDENT NAME: Osama Jarkas DATE: August 10 th, 2015

Imaging of Thoracic Endovascular Stent-Grafts

Specific Basic Standards for Osteopathic Fellowship Training in Cardiology

Māori Pathways to and Through Health Care for STEMIs in New Zealand. Summer Studentship Research by Ellie Tuzzolino- Smith

RISK STRATIFICATION for Acute Coronary Syndrome in the Emergency Department

Getting smart about dyspnea and life saving drug therapy in ACS patients. Kobi George Kaplan Medical Center Rehovot

None. Dual Antiplatelet Therapy Plus Systemic Anticoagulation: Bleeding Risk and Management. 76 year old male LINGO 1/5/2015

Low-gradient severe aortic stenosis with normal LVEF: A disturbing clinical entity

Experience of Direct Coronary Stenting at National Institute of Cardiovascular Diseases

INSTEAD at 5-year follow-up shifts the expectations for endovascular treatment

Cardiac Rehabilitation: An Under-utilized Resource Making Patients Live Longer, Feel Better

The Bioresorbable Vascular Stent Dr Albert Ko

The Cardiac Society of Australia and New Zealand

Ischemia and Infarction

Drug-Eluting Coronary Stents. Paul Montero PGY-II University of Colorado Health Sciences Center Surgical Grand Rounds Resident Debate

The Minvasys Amazonia Pax & Nile Pax Polymer Free Paclitaxel Eluting Stent Program

Vascular Quality Initiative - Carotid Artery Stent. Last Name First Name Middle Initial

California Health and Safety Code, Section

Computed Tomography, Head Or Brain; Without Contrast Material, Followed By Contrast Material(S) And Further Sections

12-Lead EKG Interpretation. Judith M. Haluka BS, RCIS, EMT-P

Journal of the American College of Cardiology Vol. 38, No. 2, by the American College of Cardiology ISSN /01/$20.

Transcription:

Namn: Titel: Mattias Törnerud, Capio St Görans sjukhus AB, Stockholm Invasiv tryckmätning FFR Har mo/agit förläsararvoden från St Jude Medical.

Intrakoronar tryckmätning, FFR i daglig praxis 1000 angio 450 PCI 100 FFR Mattias Törnerud, Medicinkliniken Capio St Görans sjukhus

Visual Interpretation of Moderate Lesions: Relation to FFR Significant Not Significant FFR > 0.75 A 53% 47% correct B 49% 51% C 56% 44% FFR < 0.75 correct A 80% 20% B 67% 33% C 87% 13% Diagnostic accuracy of visual assessment is 60% Fischer AJC; 2002;90:210-215.

QCA vs FFR 1. 0 0. 8 0. 6 FFR 0. 4 0. 2 0 40 60 80 100 Diameter stenosis%

What to do with intermediate lesions 40-80% Treat all of them Treat none of them Treat some of them Or throw the dize

65% 25%

FFR-interpretation non-signif. stenosis significant 1.0 0.80 0.75 0 Specificity : ~ 100% Sensitivity : ~ 90 % (NEJM 1996; 334: 1703-1708)

IMPORTANCE OF PERFUSION TERRITORY: Large perfusion area (myocardium) MLD, cross-sectional area and stenosis resistance are identical. MLD = 1.9 mm CSA = 4.5 mm 2 Small perfusion area (myocardium)

IDENTICAL % STENOSIS BUT DIFFERENT PHYSIOLOGIC SIGNIFICANCE. 100 FFR = 0.60 60 Large perfusion area (myocardium) 100 FFR = 0.85 85 Small perfusion area (myocardium)

PREVIOUS MYOCARDIAL INFARCTION (DECREASED PERFUSION TERRITORY): 100 60 FFR = 0.60 FFR = 0.80 100 80 Normal Myocardium SCAR Normal Myocardium Anatomic stenosis severity remins unchanged but physiologic severity has decreased. FFR accounts for those changes and always gives the right result!

Man född -54. Lindrig walk through AP Stresseko (220 W) med ischemi i septum Man född -49. AP vid löpning. Patologiskt a-prov till 240W

LAD: 0,82 LCX: 0,96 LAD: 0,88 D1: 0,92

Man född -55. AP vid rask promenad eller Uppförsbackar. Patologiskt a-prov till 200 W LAD: 0,68 Slutresultat efter stent

Man född -47. BMS (3,75 x 18) i LAD dec-09 I samband med IAP. Nu anginarecidiv vid rask promenad LAD: 0,79 Slutresultat efter DEB 3,5 x 26

Sensitivity? Specificity?

Prognostic significance of reversible ischemia at MIBI-Spect Average Annual Hard Events Iskander S, Iskandrian A E JACC 1998

Accuracy of MIBI-SPECT Male, 69-year-old, typical angina CCS 3, positive Mibi-Spect inferior wall, Referred for intervention of severe RCA stenosis

MIBI-SPECT Stress Rest Male, 69-year-old, typical angina CCS 3, positive Mibi-Spect inferior wall,

Accuracy of MIBI-SPECT

Limitations of Noninvasive Imaging: 143 Patients with angiographically significant 3 vessel disease (> 70% diameter stenosis) Thallium Scan Finding % Patients No Defect 18% Single Vessel Pattern 36% Two Vessel Pattern 36% Three Vessel Pattern 10% Lima et al. J Am Coll Cardiol 2003;42:63-70

Accuracy of MIBI-SPECT LAD: 0,65 RCA: 0,62 LCX: 0,68 Male, 53-year-old, typical angina at exercise, CCS 3 Persantin-MIBI spect negative re-assured several times. After repeated visits at outpatient clinic: referred for angio

Non-ischemic lesions do not need to be treated! The DEFER Study: 5-year Event-free Survival FFR > 0.75 FFR > 0.75 Mortality / AMI per year for non-sign lesion: < 1 % PCI rate per year for non-significant lesion : 4 % Circulation 2001; 103:2928-34)

20 % 15 10 P=0.20 P< 0.03 7.9 P< 0.005 15.7 5 3.3 0 DEFER PERFORM REFERENCE FFR > 0.75 FFR < 0.75

FLOW CHART Patient with stenoses 50% in at least 2 of the 3 major epicardial vessels Indicate all stenoses 50% considered for stenting Randomization Angiography-guided PCI FFR-guided PCI Measure FFR in all indicated stenoses Stent all indicated stenoses Stent only those stenoses with FFR 0.80 1-year follow-up

ANGIO-group N=496 FFR-group N=509 2.7 ± 0.9 2.8 ± 1.0-1329 (98%) - 874 (63%) - 513 (37%) 2.7 ± 1.2 1.9 ± 1.3 92% 94% 1359 980

ANGIO-group N=496 FFR-group N=509 91 (18.4) 67 (13.2)

ANGIO-group N=496 FFR-group N=509 91 (18.4) 67 (13.2) 15 (3.0) 9 (1.8) 55 (11.1) 37 (7.3) 47 (9.5) 33 (6.5) 113 76 43 (8.7) 29 (5.7) 16 12 27 17

absolute difference in MACE-free survival FFR-guided Angio-guided 30 days 2.9% 90 days 3.8% 180 days 4.9% 360 days 5.3%

1 Year Economic Evaluation Angio Less Costly Angio Better FFR Less Costly FFR Better QALY USD

MACCE in SYNTAX 3VD and FAME similar definition of MACCE, including CVA and excluding CKMB 3-5 x N % 20 19.1 21.5 18.6 17.2 15.8 10 11.2 8.8 10.1 14.7 11.0 0 SYNTAX UPPER MIDDLE LOWER FAME ALL TERCILE TERCILE TERCILE

Why is the results so good in the FFR group of the FAME study?

Intrinsic risk of death and myocardial infarction?

Intrinsic risk of death and myocardial infarction? chance to die or have AMI from non-ischemic lesion < 1% / year chance to die or have AMI from ischemic lesion ~ 5 % / year chance to die or have AMI from unnecessary stent ~ 3 % / year

stent them all : intrinsic risk 12% 12% stent the ischemic ones : intrinsic risk 12% 8%

Outcome of Deferred Lesions

Outcome of Deferred Lesions